How semaglutide tablets are used for weight loss in the UK

What actually happens when you take a semaglutide tablet?

The tablet contains semaglutide combined with an absorption enhancer called SNAC. Without SNAC, semaglutide would be broken down in the stomach before it could reach the bloodstream, so the two are formulated together specifically to make oral delivery possible. Once absorbed, semaglutide acts on GLP-1 receptors (the same receptors targeted by the weekly injection) reducing appetite, slowing how quickly the stomach empties, and helping the brain register fullness sooner.

The practical routine is straightforward. Each morning, before the kettle goes on, you take the tablet with no more than around 120 ml of plain water. Nothing else to drink, no food, and no other oral medicines for at least 30 minutes afterwards. Coffee, juice and even a supplement taken too soon can interfere with absorption, so the timing window matters more than it might seem. The oral semaglutide page goes into the absorption mechanism in more detail if you want the fuller picture.

Swallow the tablet whole, do not split or crush it. That is all there is to it. The simplicity is part of the point: no needles, no refrigerator, no sharps bin.

The NHS medicines information on semaglutide covers the mechanism and general cautions in plain language, and is worth reading alongside the Patient Information Leaflet that comes with your treatment.

How does the dose schedule work in practice?

The prescriber sets the pace. Treatment opens at 1.5 mg daily. Most people stay at that level for a minimum of four weeks before moving to 4 mg, then 9 mg, and finally 25 mg, the licensed maintenance dose. The steps exist for good reason: giving the body time to adjust at each level keeps gastrointestinal side effects more manageable. Rushing the ladder is not an option; the schedule is a clinical decision, not a personal one.

If side effects at a given dose are uncomfortable, a prescriber may choose to hold at that level longer rather than move up. Equally, if you are already established on the 2.4 mg weekly injection (Wegovy), clinical guidance allows moving directly to the 25 mg tablet, subject to your prescriber's assessment, you do not necessarily start again at 1.5 mg.

At nume (sorry, at our clinic) a GPhC-registered prescriber reads every consultation personally. No algorithm decides your dose or your progression. If you have questions about where you are in the schedule, our aftercare team is available seven days a week. For a broader look at what semaglutide tablets are used for and approved to treat, that page lays it out clearly, and is worth reading alongside the semaglutide tablets used for page.

One thing worth knowing: patients who switched from injection to tablet, or from Rybelsus (the diabetes-licensed oral semaglutide, which uses a different dose range of 3/7/14 mg), should be aware the Wegovy tablet schedule is entirely its own. The Rybelsus steps do not map onto it.

Who can use semaglutide tablets, and are there any situations where they are not suitable?

The MHRA licensed Wegovy tablets for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance, your prescriber will apply the correct threshold at assessment.

Semaglutide tablets are not recommended during pregnancy, whilst breastfeeding, or for anyone trying to conceive. They are not licensed for people under 18. There are also specific conditions, including a personal or family history of medullary thyroid carcinoma or MEN2, where semaglutide is contraindicated, a thorough clinical assessment covers these before any prescription is issued.

The MHRA's Yellow Card scheme allows patients to report any suspected side effects directly to the regulator, which is worth knowing especially for a medicine that received its UK approval only in mid-2026. Black Triangle status (▼) means the MHRA is collecting additional post-market data, as it does for newer medicines. That is standard practice, not a cause for alarm.

If you are weighing up the tablet against the injection, the pill alternative to Wegovy page compares the two formats directly.

What side effects do users of semaglutide tablets typically experience?

The most commonly reported effects are gastrointestinal: nausea, constipation, diarrhoea, indigestion and burping feature regularly, particularly in the early weeks or after a dose step. In the OASIS 4 phase-3 trial, around 74% of participants taking the tablet reported a GI side effect at some point, compared with roughly 42% on placebo, though for most people these effects were mild to moderate and settled over time.

Fatigue, headache and dizziness are also reported. Injection-site reactions obviously do not apply here, but some people notice a dry or slightly unsettled stomach in the first 30-minute window after taking the tablet, particularly if they accidentally ate or drank something beforehand.

The more serious effects to be aware of include symptoms of pancreatitis (severe stomach pain that spreads to the back, sometimes with vomiting) which requires urgent medical attention. Gallbladder symptoms and signs of a serious allergic reaction are also listed in prescribing information. A full side-effect list is in the Patient Information Leaflet; for a structured overview, the semaglutide tablets page covers these in more depth alongside the licensing context.

If you are ready to talk through whether the tablet is right for you, start your free consultation and a prescriber will review your details the same day.